Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Recommendation of “Reduce” from Analysts

Charles River Laboratories International, Inc. (NYSE:CRL) has been given an average rating of “Reduce” by the fifteen brokerages that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $214.00.

CRL has been the topic of several analyst reports. Evercore ISI increased their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research note on Thursday, November 7th. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target on the stock. Robert W. Baird reduced their price objective on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, September 20th. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Finally, TD Cowen lifted their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th.

Charles River Laboratories International Trading Down 1.0 %

Shares of NYSE CRL opened at $186.07 on Monday. Charles River Laboratories International has a 1-year low of $176.48 and a 1-year high of $275.00. The company has a 50-day moving average of $193.42 and a two-hundred day moving average of $199.44. The company has a market cap of $9.51 billion, a PE ratio of 23.29, a P/E/G ratio of 5.00 and a beta of 1.38. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period last year, the firm earned $2.72 EPS. As a group, equities analysts expect that Charles River Laboratories International will post 10.18 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Charles River Laboratories International

A number of institutional investors have recently modified their holdings of CRL. Wolff Wiese Magana LLC acquired a new position in Charles River Laboratories International in the 3rd quarter valued at $32,000. Versant Capital Management Inc increased its position in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares during the period. Assetmark Inc. raised its stake in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Charles River Laboratories International during the third quarter worth about $59,000. Finally, ORG Wealth Partners LLC acquired a new stake in Charles River Laboratories International during the fourth quarter worth about $56,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).